Inorganic nanoparticles in diagnosis and treatment of breast cancer

Núñez, Cristina; Estévez, Sergio Vázquez; Chantada, María Del Pilar

doi:10.1007/s00775-018-1542-z

Cited by 76 publications

(30 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanoscale materials are usually ranging from 1 to 100 nanometers (nm) [3]. Nanoparticles are classified into two major types, they are organic and inorganic NPs [4]. Carbon NPs (i.e.…”

Section: Introductionmentioning

confidence: 99%

Silver/silver chloride (Ag/AgCl) nanoparticles synthesized from Azadirachta indica lalex and its antibiofilm activity against fluconazole resistant Candida tropicalis

Aboody

2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

show abstract

“…Nanoscale materials are usually ranging from 1 to 100 nanometers (nm) [3]. Nanoparticles are classified into two major types, they are organic and inorganic NPs [4]. Carbon NPs (i.e.…”

Section: Introductionmentioning

confidence: 99%

Silver/silver chloride (Ag/AgCl) nanoparticles synthesized from Azadirachta indica lalex and its antibiofilm activity against fluconazole resistant Candida tropicalis

Aboody

2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

show abstract

“…The potential of organic nanomaterials in the design of smart systems, which deliver their cargo in response to an external stimulus, have been widely acknowledged in breast cancer therapy [19][20][21] . Nevertheless, inorganic NPs made of a metal core (iron oxide, gold or quantum dots) have been also of wide interest in cancer therapy 22 . Gold NPs (GNPs), consisting either entirely or partially of gold, turn up to be ahead as a therapeutic platform because of several advantages.…”

mentioning

confidence: 99%

Near IR responsive targeted integrated lipid polymer nanoconstruct for enhanced magnolol cytotoxicity in breast cancer

Elhabak

Osman

Mohamed

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Advances in cancer nanotechnology aim at improving specificity and effectiveness for tumor treatment. Amalgamation of different treatment modalities is expected to provide better cancer combating. Herein, We developed a long circulating nanocarrier comprising trastuzumab (TZB) surface modified polylactic-co-glycolic acid (pLGA) nanoparticles (nps) co-encapsulating magnolol (Mag) and gold nanoparticles (GNPs). A modified single step nanoprecipitation method was adopted ensuring particle coating with D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) while co-encapsulating Gnps. tZB was then anchored on nps surface using a carbodiimide chemistry. the cytotoxicity of the developed system was evaluated with and without photothermal irradiation. nps cellular uptake was then followed using confocal microscopical imaging. A hybrid matrix composed of pLGA/tpGS and surface decorated with TZB with a conjugation efficiency of ˃65%, was confirmed via ftiR, 1 HnMR. Gnps could only be included in the nps, when placed in the organic phase as evidenced by the shifted GNPs surface plasmonic resonance and confirmed via imaging coupled with energy dispersive X-ray analysis. Optimized NPs (136.1 ± 1.3 nm, −8.2 ± 1 mV and Mag encapsulation efficiency of 81.4 ± 1.8%) were able to boost Mag cytotoxicity on breast cancer cells while providing a selective multifunctional therapy with an added photothermal effect. Despite the great advances in cancer research, breast cancer remains one of the most challenging diseases risking the lives of a considerable proportion of women world wide 1. Lack of selectivity, poor drug penetration in solid tumors, multi drug resistance (MDR) with increased cells sensitivity added to the drug systemic side effects, represent some of the major barriers for a successful therapy 2. Smart drug delivery systems incorporating different cancer targeting approaches including: passive, active and stimuli responsive had been suggested to improve outcomes of cancer treatment 3,4. In this study, we focused on integrating many strategies that could potentiate the effect of a natural cytotoxic drug with potential activity against breast cancer. Magnolol (Mag), see structure Fig. S1, is a phenolic polyhydroxy compound isolated from the root and stem bark of Magnolia Officinalis 5. It had been found to inhibit proliferation and induce apoptosis in MCF-7 breast cancer cells via the intrinsic pathway with release of apoptosis inducing factor from mitochondria 5,6. Studies have also shown that Mag inhibited cell growth and HER2-mediated tumor metastasis in human HER2-cancer cells 7. Although, Mag might be considered a potential lead drug in breast cancer treatment yet, its delivery is usually hampered by poor aqueous solubility and low oral bioavailability 6,8. Hence, its incorporation in a smart nanocarrier is expected to improve its delivery characteristics and boost its anticancer properties especially with the incorporation of multifunctional adjuvants.

show abstract

“…Inorganic NPs have been classified into superparamagnetic NPs, quantum dots, quantum rods, nanoshells, silica nanoparticles, gold nanoparticles, and nanocages [ 110 ]. Some inorganic ACNPs have been developed as diagnostic biomarkers to be used as screening tools [ 110 , 111 , 112 ] and for hyperthermia therapy [ 113 , 114 , 115 , 116 , 117 , 118 , 119 ]. To a lesser extent, some of them have been explored for the tumor-selective delivery of chemotherapeutics ( Table 2 ) [ 110 ].…”

Section: Acnps For Breast Cancer Therapymentioning

confidence: 99%

“…Some inorganic ACNPs have been developed as diagnostic biomarkers to be used as screening tools [ 110 , 111 , 112 ] and for hyperthermia therapy [ 113 , 114 , 115 , 116 , 117 , 118 , 119 ]. To a lesser extent, some of them have been explored for the tumor-selective delivery of chemotherapeutics ( Table 2 ) [ 110 ].…”

Section: Acnps For Breast Cancer Therapymentioning

confidence: 99%

Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment

Juan

Cimas

Bravo³

et al. 2020

IJMS

View full text Add to dashboard Cite

Breast cancer is the most common invasive tumor in women and the second leading cause of cancer-related death. Nanomedicine raises high expectations for millions of patients as it can provide better, more efficient, and affordable healthcare, and it has the potential to develop novel therapeutics for the treatment of solid tumors. In this regard, targeted therapies can be encapsulated into nanocarriers, and these nanovehicles are guided to the tumors through conjugation with antibodies—the so-called antibody-conjugated nanoparticles (ACNPs). ACNPs can preserve the chemical structure of drugs, deliver them in a controlled manner, and reduce toxicity. As certain breast cancer subtypes and indications have limited therapeutic options, this field provides hope for the future treatment of patients with difficult to treat breast cancers. In this review, we discuss the application of ACNPs for the treatment of this disease. Given the fact that ACNPs have shown clinical activity in this clinical setting, special emphasis on the role of the nanovehicles and their translation to the clinic is placed on the revision.

show abstract

Inorganic nanoparticles in diagnosis and treatment of breast cancer

Cited by 76 publications

References 128 publications

Silver/silver chloride (Ag/AgCl) nanoparticles synthesized from Azadirachta indica lalex and its antibiofilm activity against fluconazole resistant Candida tropicalis

Silver/silver chloride (Ag/AgCl) nanoparticles synthesized from Azadirachta indica lalex and its antibiofilm activity against fluconazole resistant Candida tropicalis

Near IR responsive targeted integrated lipid polymer nanoconstruct for enhanced magnolol cytotoxicity in breast cancer

Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment

Contact Info

Product

Resources

About